Therapeutic Effect Of Different Doses Of Furazolidone On Helicobacter Pylori Eradication

Objective:With the increasing resistance of Helicobacter pylori（Hp）to antibiotics,the eradication rate of Hp decreased.This experiment compared the efficacy of different doses of furazolidone quadruple therapy in eradicating Hp,and selected a program adapted to China（or the region）.The eradication of Hp’s program.Methods:The patients were enrolled in the outpatient clinic Tongling People’s Hospital from January 2017 to June 2018.The patients were diagnosed with chronic gastritis or peptic ulcer by gastroscopy.Hp detection(¹⁴C-Urea Breath Test,gastric tissue removed under gastroscope for pathological examination)were positive.Case inclusion criteria:age 14 years or older;（2）upper gastrointestinal symptoms,and endoscopy with chronic gastritis or peptic ulcer;（3）¹⁴C-Urea Breath Test or gastroscopic removal of gastric tissue for pathological examination One positive;4)There was no formal eradication of Hp treatment;（5）The patient’s knowledge and consent to join the trial,this trial was approved by the Ethics Committee of Tongling People’s Hospital..Case exclusion criteria:（1）patients who had used proton pump inhibitors 2weeks prior to treatment or who had used antibiotics for the first 4 weeks;（2）patients who were allergic to this test drug;（3）patients with serious diseases such as liver Disease,heart disease,kidney disease,malignant tumor,etc.;（4）Patients during pregnancy,lactation and pregnancy;（5）Patients who cannot cooperate with this test,such as mental illness;（6）Other factors affect Hp eradication therapy.Case exclusion criteria:（1）patients who did not take the correct medication according to the doctor’s advice to affect the efficacy;（2）patients who experienced other diseases during treatment or who took other antibiotics and affected the observation of this trial;（3）serious side effects during treatment So that the patient can not tolerate the need to stop the drug;（4）lost to follow-up;（5）pregnancy during treatment.These eligible 116 patients were randomly divided into two groups in group A（n=57）and in group B（n=59）.patients in Group A was treated with rabeprazole 20 mg,one time every day+pectin200 mg,twice every day+amoxicillin 1000 mg,twice every day+furazolidone 100 mg,twice every day for 14 days,usedpatients in in group Bwas treated with Rabeprazole 20mg,one time every day+pectin 200mg,twice every day+amoxicillin 1000mg,twice every day+furazolidone 200mg,twice every day,a total of 14 days,After one month of withdrawal,¹⁴C-Urea Breath Test was reviewed again.The value was greater than 99Dmp Hp positive and 0-99DmpHp negative.The Hp clearance rate,adverse reaction rate and cost-effectiveness ratio（C/E）were observed and compared between the two groups.Statistical analysis was performed using SPSS 20.0 statistical software.The data were analyzed by?2tests or t test.The quantitative data were analyzed by t test.The qualitative data of the two groups were analyzed by chi-square test.The test level wasα=0.05.Results:The eradication rate of Hp in group A was 78.94%（45/57）,and the eradication rate of Hp in group B was 84.75%（50/59）,2=0.417,P=0.657.There was no difference in eradication rate between the two groups.Statistical significance（p>0.05）;PP analysis groupA Hp eradication rate was 81.82%（45/55）,group B Hp eradication rate was 89.29%（50/56）,2=1.254,P=0.263 two groups There was no significant difference in the eradication rate between Hp（p>0.05）.The incidence of adverse reactions in group A was 1.75%.The incidence of adverse reactions in group B was 3.38%,2=0.308,P=0.579.There was no significant difference in the response（p>0.05）.The cost-effective ratio of group A is the cost-effectiveness ratio of group B.Conclusion:Although there is no statistically significant difference in the eradication rate of Hp between the two groups,ITT analysis of group B Hp eradication rate of 84.75%has reached the fourth national Helicobacter pylori infection treatment consensus report recommended 80%,PP analysis Hp eradication rate of 89.29%infinitely close to 90%,B group’s cost-effective ratio is low,worthy of clinical promotion.